BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhu YG, Xiao BF, Zhang JT, Cui XR, Lu ZM, Wu N. Genetically Modified T Cells for Esophageal Cancer Therapy: A Promising Clinical Application. Front Oncol 2021;11:763806. [PMID: 34858843 DOI: 10.3389/fonc.2021.763806] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Yang K, Zhao Y, Sun G, Zhang X, Cao J, Shao M, Liang X, Wang L. Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy. Front Immunol 2023;13. [DOI: 10.3389/fimmu.2022.1081546] [Reference Citation Analysis]
2 Wang H, Xu Y, Zuo F, Liu J, Yang J. Immune-based combination therapy for esophageal cancer. Front Immunol 2022;13:1020290. [PMID: 36591219 DOI: 10.3389/fimmu.2022.1020290] [Reference Citation Analysis]
3 Zhang Z, Leng Z, Fang K, Sun M, Li Z, Kang L, Chen T, Xu M. Global research trend of esophageal squamous cell carcinoma from 2012 to 2022: a bibliometric analysis. Front Oncol 2022;12:977935. [DOI: 10.3389/fonc.2022.977935] [Reference Citation Analysis]
4 Chen L, Chen F, Niu H, Li J, Pu Y, Yang C, Wang Y, Huang R, Li K, Lei Y, Huang Y. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities. Front Immunol 2022;13:871661. [DOI: 10.3389/fimmu.2022.871661] [Reference Citation Analysis]